TEL AVIV, Israel, June 13, 2018 /PRNewswire/ -- BioLineRx Ltd.
(NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical
company focused on oncology and immunology, announced today that
its Chief Executive Officer, Philip
Serlin, will participate in a panel discussion at JMP
Securities 2018 Life Sciences Conference on Wednesday, June 20, 2018 at 3:30 p.m. (EDT). The conference will be
held at St. Regis New York,
NY.
Details of the panel discussion are as follows:
Title: Combination Strategies in Immuno-Oncology
Description: Recent clinical and commercial success with
immune checkpoint blockade and cell-based therapy approaches has
resurrected intense scientific interest in cancer immunotherapy.
With approaches ranging from immune cell mobilization to epigenetic
modulation and metabolic conditioning, panel participants will
discuss the opportunities afforded by the field as well as the
challenges posed by it, and how their individual development
strategies have been designed to maximize the chances of ultimate
success in immuno-oncology.
Key topics slated for discussion include: Next-generation
immuno-oncology therapeutics, novel targets (e.g., inhibitory
checkpoints, co-stimulatory molecules, etc.), biomarker strategies,
the future of combination therapies, and challenges associated with
drug cost and coverage.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company focused
on oncology and immunology. The Company in-licenses novel
compounds, develops them through pre-clinical and/or clinical
stages, and then partners with pharmaceutical companies for
advanced clinical development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
cancer therapy platform, which has successfully completed a Phase
2a study for relapsed/refractory AML, is in the midst of a Phase
2b study as an AML consolidation
treatment and has initiated a Phase 3 study in stem cell
mobilization for autologous transplantation; and AGI-134, an
immunotherapy treatment in development for multiple solid tumors,
which is expected to initiate a first-in-man study in mid-2018. In
addition, BioLineRx has a strategic collaboration with Novartis for
the co-development of selected Israeli-sourced novel drug
candidates; a collaboration agreement with MSD (known as Merck in
the US and Canada), on the basis
of which the Company is conducting a Phase 2a study in pancreatic
cancer using the combination of BL-8040 and Merck's
KEYTRUDA®; and a collaboration agreement with Genentech,
a member of the Roche Group, to investigate the combination of
BL-8040 and Genentech's atezolizumab in several Phase 1b/2 studies for multiple solid tumor indications
and AML.
For additional information on BioLineRx, please visit the
Company's website at www.biolinerx.com, where you can review the
Company's SEC filings, press releases, announcements and events.
BioLineRx industry updates are also regularly updated on Facebook,
Twitter, and LinkedIn.
Contact:
PCG Advisory
Vivian Cervantes
Investor Relations
+1-646-863-6274
vivian@pcgadvisory.com
or
Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipihai5@gmail.com
View original
content:http://www.prnewswire.com/news-releases/biolinerx-to-participate-at-jmp-securities-2018-life-sciences-conference-300665513.html
SOURCE BioLineRx Ltd.